Sebi Cancels Registration of Religare Capital Markets, 11 Others
India's Securities and Exchange Board (Sebi) has revoked the registrations of Religare Capital Markets and 11 other entities for failing to pay required renewal fees for research analyst registrations between May 2024 and November 2025. The action was taken after the firms could not substantiate their claims during show-cause proceedings, with Sebi citing investor protection concerns.
Sebi has revoked the registrations of Religare Capital Markets and 11 other entities due to their failure to pay required renewal fees for research analyst registrations. According to the announcement, the renewal fees were due between May 2024 and November 2025. The affected entities were issued show-cause notices and provided an opportunity to respond to the regulator's inquiries. However, the companies could not adequately substantiate their claims regarding non-payment, leading Sebi to proceed with cancellation of their registrations.
The regulatory action underscores Sebi's commitment to maintaining compliance standards within India's capital markets infrastructure. Research analyst registrations are critical regulatory requirements that ensure market participants meet specified qualifications and ethical standards. When firms allow registrations to lapse without timely renewal fee payment, they risk operating in an unregulated capacity, which can expose investors to potential misuse or substandard research practices. By revoking registrations of non-compliant entities, Sebi aims to safeguard retail and institutional investors from entities operating without valid credentials. The cancellations also reinforce the importance of maintaining administrative compliance among registered market participants. This action may prompt other research firms and capital market entities to review their registration renewal schedules and fee payment processes to avoid similar regulatory consequences.
Source: Markets-Economic Times
This article is an editorial summary sourced from third-party news providers and is produced by marketkin.com for informational purposes only. It does not constitute investment advice. Disclaimer